Teva to Buy Allergan Generics for $40.5 Billion - WSJ
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
Teva to Buy Anda from Allergan | CHEManager
Teva buys Allergan: 3 reasons why it's a blockbuster deal | Fortune
Allergan to Sell Teva Shares to J.P. Morgan | Ctech
New York Opioid Trial: Allergan Settlement Leaves Teva as Last Target - Bloomberg
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Teva Pharmaceuticals to Buy Allergan's Generics Business - The New York Times
AG Reaches $33.3M Agreement with Teva, Allergan; Opioid Makers Agree to Restrictions on Sales, Marketing - InDepthNH.orgInDepthNH.org
Teva deal lets us double down on brands: Allergan CEO
Teva buys Allergan's generic drug unit for $40.5B
/cloudfront-us-east-1.images.arcpublishing.com/gray/NTZZMVWJCVHFXDGT7B7G5ZMBKQ.jpg "Attorney General Stein announces settlement finalization with Teva Pharmaceuticals and Allergan, over $180 million to go to North Carolina")
Attorney General Stein announces settlement finalization with Teva Pharmaceuticals and Allergan, over $180 million to go to North Carolina
Allergan sells generic drug unit to Israel's Teva for $40.5 billion - Los Angeles Times
Allergan: Restasis Is Under Siege By Mylan And Teva (NYSE:AGN) | Seeking Alpha
Settling a post-buyout hangover, Allergan gives Teva a $700M remedy | Fierce Pharma
Teva-Acquire-Allergans-Generics-Business
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/LCGCPK3EYBF3PJZYOYFN26JDWQ.jpg "Teva buying Allergan, drops Mylan bid")
Teva buying Allergan, drops Mylan bid
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
San Francisco reaches $58 mln opioid settlement with Teva, Allergan | Reuters
Teva deal lets us double down on brands: Allergan CEO
Teva, Allergan reach $161.5 mln opioid settlement with West Virginia | Reuters
Allergan to sell a quarter of its Teva stake in first quarter of 2018 | Reuters
